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Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by pro-
longed or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. 
HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like sub-
stances, cannabis, methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, 
and psychostimulants. The recent emergence of novel psychoactive substances (NPS) 
posed a critical concern regarding the new onset of psychiatric symptoms/syndromes, 
including cases of HPPD. Symptomatology mainly comprises visual disorders (i.e., geo-
metric pseudo-hallucinations, haloes, flashes of colors/lights, motion-perception deficits, 
afterimages, micropsia, more acute awareness of floaters, etc.), even though depressive 
symptoms and thought disorders may be comorbidly present. Although HPPD was first 
described in 1954, it was just established as a fully syndrome in 2000, with the revised 
fourth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 
HPPD neural substrates, risk factors, and aetiopathogenesys still largely remain unknown 
and under investigation, and many questions about its pharmacological targets remain 
unanswered too. A critical mini review on psychopathological bases, etiological hypothe-
sis, and psychopharmacological approaches toward HPPD, including the association with 
some novel substances, are provided here, by means of a literature search on PubMed/
Medline, Google Scholar, and Scopus databases without time restrictions, by using a 
specific set of keywords. Pharmacological and clinical issues are considered, and practi-
cal psychopharmacological recommendations and clinical guidelines are suggested.
Keywords: hallucinogen-persisting perception disorder, novel psychoactive substances, hallucinogens, 
hallucinations, flashbacks, palinopsia
inTRODUCTiOn
Hallucinogen-persisting perception disorder (HPPD) is a long-lasting and potentially permanent 
syndrome characterized by a spontaneous recurrence of perceptual/visual disturbances which are 
reminiscent of those generated while a subject was intoxicated with hallucinogens. According to 
TAble 1 | Main clinical and psychopathological characteristics in HPPD.
Psychopathological and clinical 
features
Description
Teleopsia Objects are perceived much further away 
than they actually are
Pelopsia Objects are perceived nearer than their 
actual size
Macropsia Objects are perceived larger than their 
actual size
Micropsia Objects are perceived smaller than their 
actual size
Criticism/egodystonic psychosis Patient manifests criticism toward own 
thoughts and perceptual disturbances, as 
well as experiencing perceptual disorders 
perceived as inconsistent with one’s self 
concept or ego state
Depersonalization A state in which some individual feels that 
either he/she him/herself or the outside 
world is unreal
Derealization A state in which an individual feels a 
detachment within the self-regarding one’s 
mind or body or being a detached observer 
of oneself (e.g., Feeling like being inside a 
transparent bubble)
Feeling of body being light or heavy
Visual trailing Transient disturbance of visual motion 
perception of unknown origin (i.e., subject 
perceives a series of discrete stationary 
images trailing in the wake of otherwise 
normally moving objects)
Haloes around objects A geometric shape, usually in the form of a 
disk, circle, ring, or rayed structure around 
an object really present
Afterimages/palinopsia An image that continues to appear in one’s 
visual field after the exposure to the original 
image has ceased
Other visual disturbances Flashes of color
Intensified colors
Colored images
Geometric imagery
False perception of movement of images in 
the peripheral-field
HPPD, hallucinogen-persisting perception disorder.
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the Fifth Version of Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5), HPPD is defined as the following criteria (1):
(A) following cessation of use of a hallucinogen, the reexpe-
riencing of one or more of the perceptual symptoms that 
were experienced while intoxicated with the hallucinogens 
(e.g., geometric hallucinations, false perceptions of move-
ment in the peripheral visual fields, flashes of color, inten-
sified colors, trial images of moving objects, positive after 
images, haloes around objects, macropsia, and micropsia);
(B) the symptoms in criterion (A) cause clinically significant 
distress or impairment in social, occupational, or other 
important areas of functioning;
(C) the symptoms are not due to a general medical condition 
(e.g., anatomical lesions and infections of the brain, visual 
epilepsies) and are not better accounted for by another 
mental disorder (e.g., delirium, dementia, schizophrenia) 
or hypnopompic hallucinations.
Before diagnosing an HPPD, post-traumatic stress disorder, 
depersonalization, derealization, and hallucinogen-induced 
psychotic mood or anxiety disorders should be excluded (2). 
Moreover, other causes of visual disturbances should be inves-
tigated and excluded, such as anatomical lesions, brain infec-
tions, epilepsy, schizophrenia, delirium state, or hypnopompic 
hallucinations (2). Furthermore, an association between the first 
intake, frequency, and quantity of drug taken and the likelihood 
of developing an HPPD has not been demonstrated, as has been 
the onset of the disorder following a single hallucinogenic experi-
ence (3).
epidemiology
Overall, prevalence of HPPD has been generally considered low 
(2). However, limited publications suggested that chronic visual 
disturbances may be relatively common among hallucinogens’ 
users. It has often been assumed that HPPD may be a severe 
clinical manifestation of the drug-induced visual changes (3–5). 
While the probability of flashbacks occurring in the wake of 
hallucinogen use may vary from 5 to 50% among hallucinogens’ 
users (6, 7), the probability of an HPPD being manifested is 
lower (3).
Historical background
Hallucinogen-persisting perception disorder was first described 
in 1954 (8). Subsequent observations have been then described 
(3, 4, 8–12). Horowitz (10) first introduced the term flashbacks, 
referring to recurrent and spontaneous perceptual distortions 
and unbidden images. When these “flashbacks” present as recur-
rent, but without a current acute, or chronic hallucinogen intake, 
the disturbance is referred to as HPPD. Horowitz (10) classified 
also three types of visual flashbacks: (a) perceptual distortions  
(e.g., seeing haloes around objects); (b) heightened imagery  
(e.g., visual experiences as much more vivid and dominant in 
one’s thoughts); and (c) recurrent unbidden images (e.g., subjects 
see objects that are not there). HPPD has been introduced under 
the diagnosis of Post- hallucinogen Perception Disorder in 1987 
within the DSM-III-R (13). Subsequently, the DSM-IV-TR (14) 
recognized the syndrome as Hallucinogen-Persisting Perception 
Disorder (Flashbacks) (code 292.89) (15). The disorder was con-
firmed as nosological entity as well in the DSM-5 (1).
Phenomenology
Hallucinogen-persisting perception disorder is characterized 
by a plethora of visual disturbances (e.g., geometric imagery, 
afterimages, false perceptions of movement in the peripheral 
fields, flashes of light, etc.) (3) (Table 1), including pseudohal-
lucinations. It has been also associated with a LSD (lysergic 
acid diethylamide)-like dysphoria, panic attacks, and depressive 
symptomatology. Visual disturbances may be episodic, stress or 
substance-induced, or persistent. However, the episodes may last 
3Orsolini et al. Novel Psychoactive Substances and HPPD
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for 5 years or more and the symptomatology is disliked by patients 
(10). While a flashback is usually reported to be infrequent and 
episodic, HPPD is usually persisting and long-lasting. Moreover, 
some HPPD subjects report that adaptation to the dark takes 
significantly longer compared with the general population (16). 
Moreover, HPPD has been associated with abnormal results for 
tests of visual function, suggesting disinhibition in the process-
ing of visual information (4, 16). The subject does not develop 
any paranoid misinterpretation related to and does not believe 
that their own visual hallucinogenic experiences currently occur 
(3). Therefore, it has been supposed that there is involvement of 
the primary visual cortex, the first cortical area responsible for 
geometric processing of visual input (17). Further data coming 
from clinical, psychological, and neurophysiological sources may 
suggest specific physiological changes in the visual system func-
tion implicated in the onset of hallucinations after the intake of 
psychedelics/hallucinogens (5). Table 1 summarizes all clinical 
and psychopathological characteristics associated with an HPPD.
Aetiopathogenesys
The pathogenesis of HPPD is currently unknown, even though it 
has been frequently reported to be associated with the intake of 
LSD (4, 16, 41). However, HPPD has also been reported following 
the consumption of all substances with hallucinogenic properties 
which possess pharmacological and clinical effects resembling 
those experienced with LSD by serotoninergic 5-HT2A (42), such 
as cannabis (18, 43, 44), 3,4-methylenedioxymethamphetamine 
(MDMA, aka “ecstasy”) (45–47), and the recently marketed 
novel psychoactive substances (NPS). In fact, the advent of NPS 
facilitated the onset of new psychopathologies and new clinical 
manifestations, including cases of HPPD, particularly follow-
ing the intake of synthetic cannabinoids (SCs) and other new 
synthetic psychedelics and hallucinogens, which facilitated the 
reoccurrence of this disorder, by posing a new clinical concern to 
clinicians (19, 20, 48, 49).
Types of HPPD
Two types of HPPD have been proposed here, accordingly to 
Lev-Ran (40). Type-1 HPPD, consistent with the definition of 
flashback provided by the ICD-10 (50), is characterized by brief 
reexperiences of altered perception, mood, and/or consciousness, 
as previously experienced during a hallucinogenic intoxication. 
Symptomatology may be pleasurable and even controllable. 
They may appear days to months after the hallucinogen-induced 
experience. The subject is usually aware of the unreality of their 
own experience. The perception of time may be altered. Visual 
perceptions usually comprise perceived increased color intensity, 
dimensionality, vibrancy, illusory changes, and movements of a 
perceived object. Type-1 HPPD comprises the flashbacks defini-
tion, while type-2 HPPD has been used to indicate the HPPD 
definition elaborated by Abraham (3) as well proposed in the 
DSM-5. The symptoms usually include palinopsia (afterimages 
effects), the occurrence of haloes, trails, akinetopsia, visual snows, 
etc. Sounds and other perceptions are usually not affected. Visual 
phenomena have been reported to be uncontrollable and disturb-
ing. Symptomatology may be accompanied by depersonalization, 
derealization, anxiety, and depression (3).
The present systematic mini review aims at providing an over-
view of HPPD, by specifically focusing on both clinical manifes-
tations and psychopharmacological approaches, in general, and 
among NPS users.
MATeRiAlS AnD MeTHODS
Search Sources and Strategies
A critical mini review was conducted, following the methods rec-
ommended by the Cochrane Collaboration (51) and the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines (52). Searches were carried out by using 
PubMed/Medline, Google Scholar, and Scopus. We combined the 
search strategy of free text terms and exploded MESH headings for 
the topics of HPPD and NPS as follows: ((Hallucinogen Persisting 
Perception Disorder [Title/Abstract] OR HPPD [Title/Abstract])) 
OR ((Hallucinogen Persisting Perception Disorder [Title/Abstract] 
OR HPPD [Title/Abstract])) and ((novel psychoactive substances 
[Title/Abstract]) OR (NPS[Title/Abstract])). All articles through 
August 15, 2017 without time restriction were selected. In addi-
tion, the authors performed further secondary searches by using 
the reference listing of all eligible papers.
Study Selection
We considered studies about HPPD, and whenever available, 
evaluating the relationship between HPPD and NPS. The authors 
examined all titles/abstracts and obtained full texts of potentially 
relevant papers. Two reviewers (LO and DP), independently and 
in duplicate, read the papers and selected papers according to 
the inclusion criteria. Duplicate publications were excluded. All 
the articles identified by the data sources, reporting original data 
related to HPPD in general and, more specifically, among NPS 
users, were considered in the present review. All experimental 
and observational study designs, including case reports and case 
series, were included as limited data have been published so far. 
Narrative and systematic reviews, letters to the editor, and book 
chapters were excluded, even though they were used for retrieving 
further secondary searches. To be included in the present review, 
studies were required to meet the following criteria: (a) empirical 
and peer-reviewed study; (b) at least an abstract with estimates 
and/or full results available/complete; (c) investigate HPPD in 
general and more specifically among NPS users; (d) human stud-
ies; and (e) provide data on psychopathological features and/or 
psychopharmacological treatments in these cases.
Data extraction and Management
LO and DP independently extracted the data on participant 
characteristics, intervention details, and outcomes measures. 
Disagreements were resolved by discussion and consensus with 
a third member of the team (DDB). Data were collected using an 
ad hoc developed data extraction spreadsheet.
Characteristics of included Studies
The set of keywords initially generated 260 results (Figure  1). 
A total of 31 papers were excluded because of duplicates; 7 papers 
were excluded because they did not provide relevant data useful 
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Abstracts identified through
PubMed search (n = 260)
Abstracts excluded, with reasons (n = 38): 
- Duplicates (n = 31)
- Not written in English (n = 7) 
Full-text articles excluded, with reasons (n = 198):
- Reviews/commentaries/letters/meta-analysis (n = 6)
Full-text articles assessed - Animal studies (n = 139)
for eligibility (n = 222) - Unavailable (n = 6)
- unrelated to topic (n = 47)
Full-text articles included in 
qualitative synthesis (n =24)
FigURe 1 | Selection of retrieved studies.
for the aims of our papers (due to the lack of an English abstract). 
Of the remaining 222 studies, further 186 studies were excluded 
because they did not meet the inclusion criteria or because they 
were non-human studies. Of the remaining 36 papers, 6 papers 
were excluded because they were reviews, letters to editors, or 
metanalyses; however, 6 papers were not included here due to 
the lack of an available full text or an abstract useful for collect-
ing relevant data. Finally, a total of 24 papers were included and 
accounted for in our analysis. Table 2 shows the main character-
istics (study design, sample size, main outcomes, and findings) of 
all studies reviewed here.
ReSUlTS
Studies on Psychopharmacotherapy  
of HPPD
An observational study recruited 21 HPPD subjects who were 
treated with benzodiazepines and/or phenothiazines (3). Among 
subjects receiving benzodiazepines, eight out of nine reported a 
reduction in intensity/frequency of visual disorders. Most (11 out 
of 12) phenothiazine-treated subjects described an exacerbation 
of HPPD (3). A case series reported three cases of HPPD, treated 
with risperidone, who presented a worsening of visual percep-
tions and panic symptomatology (21). Lerner et al. (22) described 
two LSD-induced HPPD male subjects who reported an improve-
ment of symptomatology following naltrexone (50  mg daily) 
treatment (22). Another case report described a 22-old-year male 
who developed HPPD after 8-month discontinuation of LSD (22). 
The subject significantly improved after sertraline (100 mg/daily) 
treatment (23). An open-label pilot study recruited eight HPPD 
drug-free patients who were consecutively treated with 0.025 mg 
of clonidine, three times a day, for 2 months, in order to evalu-
ate the efficacy of drug in treating persistent visual disturbances 
associated with the intake of LSD (24). LSD-related flashbacks 
demonstrated a good response to clonidine (24). A study des-
cribed two HPPD outpatients who efficaciously responded to 
clonazepam (25). An HPPD patient with a comorbid depressive 
symptomatology and a prior history of cannabis, ecstasy and LSD 
abuse, clinically responded to 6 mg daily of reboxetine (26). An 
open-label study recruited 16 drug-free patients affected with 
HPPD with anxiety features for at least 3 months who received 
2 mg daily of clonazepam for 2 months (27). Subjects reported 
a significant relief of anxiety and HPPD symptomatology with 
only mild symptomatology during the clonazepam treatment, 
suggesting the efficacy of clonazepam in these cases (27). Espiard 
et al. (18) presented a case report of an HPPD patient with a previ-
ous mixed intoxication with psilocybin and cannabis. Perceptual 
disorders appeared after a single psilocybin consumption. The 
subject re-experienced the symptomatology the following day 
during another cannabis snort. Moreover, symptomatology was 
recurrent daily with an attenuation after discontinuation until 
6  months after he had stopped cannabis. Initially, he received 
amisulpride (100  mg/daily) treatment, subsequently stopped 
due to sedative effects. Then he started with olanzapine (5 mg/
daily) which caused an exacerbation of symptomatology. Finally, 
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TAble 2 | Summary of all included studies.
Study Study design Sample characteristics Substance implicated Psychopharmacological 
treatment (dosage)
Summary of findings
(3) Observational 
study
21 HPPD LSD BZDs (N/A) An improvement was observed among HPPD subjects following the 
use of BDZs; while phenothiazine worsened HPPDPhenothiazines (N/A)
(18) Case report 1 M, 18 years, student with a history of anxiety disorder Cannabis and psilocybin Amisulpride (100 mg daily) Combination of risperidone and sertraline ameliorated HPPD 
symptomatology after 6 months of treatmentOlanzapine (5 mg daily)
Risperidone (2 mg daily)
Sertraline (150 mg daily)
(19) Case reports 2 HPPD (DSM-IV-TR criteria):
 1. M, 26 years, college student who developed HPPD 
with recurrent panic attacks after discontinuation of 
SC intake
 2. M, 24 yr, who developed HPPD experienced with 
anxiety features after discontinuation of SC intake
SC Clonazepam (1 mg/daily) Clonazepam improved HPPD symptomatology
(20) Case report M, 18 years, with a history of heavy daily use of 
cannabis and SC who experienced HPPD
SC Clonazepam (6 mg/daily) For 3 years after SC consumption, the patient occasionally 
reexperienced the same symptoms developed during acute 
intoxication. These symptoms appeared during heavy cannabis 
consumption or in periods of boredom and inactivity
(21) Case series 3 HPPD (DSM-IV criteria):
•	 Case 1: F (first LSD usage: 14 years; at 21 years, first 
acute onset of an LSD-like euphoria and persistent 
visual distortions, e.g., trails of objects, particles in air, 
round objects)
•	 Case 2: M, 22 years, college student (first LSD 
usage: 15–18 years; at 20 years, first acute onset of 
persistent visual symptoms of afterimages, trailing of 
stimuli, orange/blue haloes around objects)
•	 Case 3: M, 40 years, married, builder (first LSD 
usage: 18 years; at 18 years, first acute onset of dots 
on a blank wall, intensification of lights, trails of his 
hand, anxiety, depression)
LSD RIS:
•	 2–3 mg/daily
•	 1–6 mg/daily
•	 1–2 mg/daily
RIS worsened LSD-like panic and visual symptoms
(22) Case series 2 HPPD (DSM-IV criteria) LSD Naltrexone (50 mg/daily) Naltrexone caused a dramatic improvement in HPPD 
symptomatology. The remission was sustained also after 
discontinuation of naltrexone
(23) Case report M, 22 years who developed HPPD after an 8-month 
history of LSD abuse
LSD Sertraline (100 mg/daily) Sertraline determined initially an exacerbation of HPPD 
symptomatology, then it attenuated symptoms after 1 month’s 
administration
(24) Observational 
study
8 HPPD LSD Clonidine (0.025 mg for 3 
times/daily) for 2 months
Clonidine may alleviate LSD-related flashbacks
(25) Case series 2 HPPD outpatients LSD Clonazepam Clonazepam was efficacious in reducing HPPD symptomatology
(26) Case report 1 HPPD with comorbid MDE MDMA, LSD, and 
cannabis
Reboxetine (6 mg/daily) Reboxetine did not exacerbates visual disturbances either recurrence 
of depressive features
(27) Observational 
study
16 HPPD with anxiety features LSD Clonazepam (2 mg/daily) Clonazepam was efficacious in attenuating both anxiety and HPPD 
symptomatology
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Study Study design Sample characteristics Substance implicated Psychopharmacological 
treatment (dosage)
Summary of findings
(28) Case report F, 33 years with HPPD LSD Sertraline (200 mg daily) Lamotrigine reduced almost completely visual disturbances of HPPD
Citalopram (20–30 mg daily)
Fluoxetine (20 mg daily)
Risperidone (0.5–1 mg daily)
Lamotrigine (100–200 mg daily)
(29) Case report M, 36 years with HPPD LSD, cannabis, alcohol, 
cocaine
Clonidine Clonidine did not improve symptomatology; while lamotrigine was 
associated with a significant symptomatology improvementLamotrigine (200 mg/daily)
(30) Case report F, 38 years with HPPD (DSM-5 criteria) LSD Risperidone (0.5 mg/daily) Significant reduction in the frequency and intensity of panic attacks 
and perceptual disturbances within 3–4 weeks with low dosages of 
risperidone
(31) Case report M, 30 years, presented to the emergency department 
after surviving two subsequent suicide attempts by 
hanging, with a previous history of bipolar disorder and 
who developed HPPD
Cannabis Citalopram (40 mg/daily) Patient poorly responded to treatment and was found to have 
committed suicideLSD Lamotrigine (50 mg/daily)
PCP Mirtazapine (15 mg/daily)
Cocaine
(32) Web-based 
survey
626 hallucinogens’ users Cannabis N/A Long-term perceptual disturbances were mainly reported among LSD 
usersMDMA
Psilocybin
LSD
Ketamine
(33) Web-based 
survey
3139 hallucinogens’ users Several hallucinogens 
(including cannabis, 
MDMA, psilocybin, LSD, 
ketamine, Salvia divinorum)
N/A LSD appeared to be the most robust predictor of HPPD
(34) Case reports 2 HPPD (DSM-5 criteria):
 1. M, 24 years, university student
 2. F, 25 years, university student
LSD N/A Both cases reported the appearance of visual disturbances that were 
not originally experienced during LSD intoxication
(35) Case–control 
study
12 inpatients with schizophrenia and HPPD vs.  
14 inpatients with schizophrenia without HPPD  
(DSM-IV-TR criteria)
LSD N/A No significant differences have been found between two groups 
in sociodemographic and clinical features. Individuals with 
schizophrenia and HPPD reported the ability to identify specific 
precursory cues for the appearance of HPPD-associated perceptual 
disturbances
Cannabis
MDMA
(36) Case–control 
study
4 HC vs. 1 M, 23 years, HPPD patient Cannabis N/A Cannabinoids may have a direct effect on the retina and retinal 
pigment epithelium function which may be involved in perceptual 
disturbances experienced in cannabis-induced HPPD
(37) Case–control 
study
37 inpatients with schizophrenia and HPPD vs.  
43 inpatients with schizophrenia without HPPD  
(DSM-IV-TR criteria)
LSD N/A No significant differences found between two groups in 
sociodemographic features. Individuals with schizophrenia and HPPD 
reported lower general psychopathology and negative symptoms 
scores compared with individuals without HPPD
TAble 2 | Continued
(Continued)
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he was treated with risperidone (2 mg/daily). Then, it was coad-
ministered with sertraline (150  mg/daily) for the treatment of 
persisting dysphoric mood and recurrent anxiety-like symptoms. 
After 6 months of combination risperidone and sertraline, HPPD 
disappeared (18). A 33-year-old female developed an HPPD fol-
lowing the recreational use/abuse of LSD for a year at the age of 
18 (28). Approximately, 2–3 weeks after the last drug intake, the 
subject developed persistent visual disturbances (a sort of attenu-
ated flashbacks), like those experienced during an acute LSD 
intoxication, which lasted for over 13 years, with a little change 
in intensity and frequency. Despite the patient receiving several 
psychopharmacological treatments (e.g., sertraline, citalopram, 
fluoxetine, risperidone, etc.), only a year-long trial of lamo-
trigine (100–200 mg/day) improved abnormal visual perceptions. 
In addition, no significant cognitive deficits (i.e., memory 
functioning, attention span, visual-construction, and frontal-
executive functioning) were detected, but an underperformance 
in the phasic attention. A follow-up after 19 months showed a con-
tinued improvement in attention performance. Brain magnetic 
resonance imaging scans, electroencephalograms, median nerve 
somatosensory, and visual evoked potential tests were all reported 
normal (28). A case report described a 36-year-old HPPD subject 
who experienced persistent visual disturbances after recreational 
use of LSD, cannabis, alcohol, and cocaine (29). The patient was 
initially treated with a 3-month course of clonidine without any 
improvement; then, he was treated with lamotrigine (200  mg 
daily) for a 7-month period with a significant improvement of 
his visual disturbances and overall mental well-being (29). A case 
report described a woman who experienced panic attacks and 
persistent “re-experience phenomena” characterized with flash-
backs to the first trip with LSD. She responded to 0.5 mg daily of 
risperidone (30). A case report described an HPPD patient with a 
history of bipolar disorder, a previous consumption of LSD, can-
nabis, cocaine, and phencyclidine (PCP) (30). The patient, even 
though treated with lamotrigine, citalopram, and mirtazapine, 
committed suicide, after the hospitalization (31).
Studies on the Clinical Manifestation  
and Psychopathology in HPPD
A web-based questionnaire study investigated users’ percep-
tions of the benefits/harms of hallucinogens’ intake, including 
the occurrence and prevalence of flashback phenomena and/or 
HPPD (32). Only 10% of the sample recruited reported long-term 
perceptual changes, which they would “rather not have but could 
live with,” while 1% reported changes that “drove them mad” (32). 
Of these, 39% reported them following the use of LSD, 11% after 
psilocybin, 9% after MDMA and cannabis, 4% ketamine, and 1% 
alcohol. Despite 22% of subjects reported having experienced a 
“flashback”, only 3% of subjects experienced a “negative” flashback 
(32). A web-based questionnaire investigated abnormal visual 
experiences among 3139 hallucinogens’ users (33). Each par-
ticipant had their drug-use history (i.e., classical serotonergic hal-
lucinogens, including LSD, psilocybin, dimethyltryptamine, etc.; 
NMDA antagonists, including ketamine and dextromethorphan; 
MDMA, anticholinergic-containing Datura plants; cannabis; 
Salvia Divinorum, etc.); psychiatric and neurological history; 
and their visual experiences investigated. Several drugs with St
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hallucinogenic properties have been statistically associated with 
unusual visual experiences, even though LSD seemed to be the 
most frequently reported among the HPPD-like cases (33). Lerner 
et al. (19) reported two case reports with a prior history of LSD 
intake, who experienced new visual disturbances, not previously 
appeared during the first LSD intoxication, after totally stopping 
substance use (34). A pilot study recruited 26 inpatients affected 
with schizophrenia and concomitant self-reported past LSD use 
who presented with HPPD (n = 12) or without HPPD (n = 14) 
(35). No significant differences in demographic, clinical features, 
adverse effects, and response to medications have been reported 
between the two groups. Furthermore, the authors reported that 
patients with schizophrenia and concomitant HPPD were able 
to distinguish HPPD symptoms from hallucinations related to 
their own psychotic state (35). A case-control study recruited a 
cannabis-user who developed HPPD and four healthy controls in 
order to evaluate the differences in their ophthalmological state 
(36). Ophthalmological examination did not report clinically sig-
nificant abnormal values for the HPPD patient or for any healthy 
controls, even though the HPPD subject reported a slightly 
reduced fast oscillation rate, a diminished standing potential of 
the slow oscillations, and a light peak within normal range result-
ing in higher Arden ratios (36). Another study by Lev-Ran et al. 
(37) compared the characteristics of schizophrenic patients with a 
prior LSD consumption who developed HPPD (n = 37) with those 
who did not develop HPPD (n = 43). No significant differences in 
sociodemographic characteristics were reported between the two 
groups. Individuals with schizophrenia and HPPD showed lower 
scores for negative symptoms (p < 0.001), general psychopathol-
ogy (p = 0.02), and total symptoms (p < 0.001), as measured with 
Positive and Negative Symptomatology Scale (PANSS), as com-
pared with those reported in the group of schizophrenics without 
HPPD (37). A case report described a patient with a prior history 
of cannabis, alcohol, and LSD sporadic recreational consumption, 
who developed LSD-induced “Alice in Wonderland Syndrome” 
and HPPD after discontinuation of all substances (38). A question-
naire specifically identified prevalence and characteristics of self-
reported altered perception experiences in hallucinogens’ users 
(39). The survey concluded that HPPD may be due to a subtle over-
activation of predominantly neural visual pathways which in turn 
may worsen anxiety after ingestion of arousal-altering drugs (39). 
A study explored triggers associated with type-1 and type-2 HPPD 
following the use of LSD, by recruiting 40 outpatients affected with 
HPPD (40). The findings reported differences in terms of visual 
disturbances and triggers between the two HPPD types. The most 
common types of visual disturbances were slow movement of still 
objects (among type-1 HPPD) and trailing phenomena (among 
type-2 HPPD). Furthermore, type-1 HPPD subjects were more 
likely to experience disturbances in a dark environment (40).
Studies on nPS and HPPD
A case series described two cases of HPPD induced by SCs (19). 
A recent case report described a patient with a previous history of 
heavy daily use of cannabis admitted to an Addiction Treatment 
Unit who reexperienced visual hallucinations and disturbances, 
like those who experienced during acute consumption of SC, in 
the days following SC consumption (20).
DiSCUSSiOn
Several case reports of reoccurring or prolonged persistent visual 
perceptual disturbances (HPPD) have been described occurring 
within a certain time frame after cessation of some hallucinogenic 
drugs (2, 53, 54).
The present critical mini review presents several limitations. 
First, given the paucity of double-blind, placebo-controlled/
case-control studies, we included case reports and case series as 
well, and studies with small sample size which may greatly limit 
the generalizability of findings reviewed here. Second, methodo-
logical strategies (sample size, study design, diagnostic criteria, 
etc.) may vary greatly in several studies retrieved. Most studies 
included here investigated HPPD cases following the intake of 
LSD, even though other isolated cases described incidents follow-
ing the intake of other serotonergic hallucinogens, and cannabis. 
Furthermore, most studies here retrieved do not specifically 
distinguish between the two types of HPPD, as previously dis-
cussed, by limiting the complete understanding of the clinical 
symptomatology and manifestation.
The recent wave of novel substances available on the market, 
includes several novel cannabimimetics, novel hallucinogens 
(e.g., NBOMe compounds), and new LSD derivatives (48, 49). 
With regard to these substances, the prevalence of HPPD among 
NPS users is difficult to detect, due to the limited number of 
published reports, mainly due to the lack of knowledge among 
the clinicians and the consequent difficulty in the diagnosis (48). 
However, the specific pharmacological profile of some psycho-
stimulants and hallucinogens may likely determine an increasing 
number of NPS-induced HPPD cases (48, 49). In fact, despite sev-
eral studies reporting a higher occurrence of HPPD following the 
consumption of LSD, HPPD has been associated with a broader 
range of substances, e.g., natural and synthetic serotonergic 
5-HT2A receptor hallucinogens (44, 47, 55–57), including the most 
recent new synthetic psychostimulants and hallucinogens (19, 20, 
48, 49). In particular, the intake of SCs, which are CB1 receptor 
full agonists and possess indole-derived structures, which may 
itself facilitates the 5-HT2A receptor dysfunction (48, 58, 59), has 
been associated with the onset of perceptual disorders, even after 
a total discontinuation, as it has been supposed that SCs may 
provoke a partial/total reminiscence of the previous perceptual 
experience in predisposed and susceptible NPS users (20, 60, 61).
Furthermore, the pharmacotherapy of HPPD may be differ-
ent from study to study, as only few studies have been published 
so far and any recommendations are based almost entirely on 
non-controlled studies of small patient populations or single 
case reports (3, 18–31). Risperidone is a highly potent antagonist 
of both postsynaptic 5-HT2 and dopamine D2 receptors (62). As 
5-HT2 receptor antagonists are effective in treating hallucinations 
among schizophrenic patients, it has been previously supposed 
that risperidone would be efficacious in treating HPPD (18, 30). 
However, most studies reviewed here reported a worsening of 
symptomatology, particularly visual disturbances and an abrupt 
onset of panic attacks after the intake of risperidone among LSD 
users (21, 28). The symptomatology tended to return to baseline 
levels when risperidone was discontinued (21, 28). A case report 
described an improvement in HPPD symptomatology with a 
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